Recent Posts
- Antag Therapeutics demonstrates compelling potential of its novel GIPR antagonist for obesity, reporting excellent tolerability in Phase 1 and enhanced weight loss in amylin combination study
- Antag Therapeutics expands senior team to support clinical progress
- Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment
- Experienced Industry Leader Dr. Joerg Moeller Appointed as Chief Executive Officer of Antag Therapeutics
- Antag Therapeutics Announces €80 Million Series A Financing
Recent Comments
No comments to show.